Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
Standard
Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. / Eichelberg, Christian; Minner, Sarah; Isbarn, Hendrik; Burandt, Eike; Terracciano, Luigi; Moch, Holger; Kell, Alexandra; Heuer, Roman; Chun, Felix K; Sauter, Guido; Fisch, Margit; Tennstedt, Pierre.
in: WORLD J UROL, Jahrgang 31, Nr. 4, 2013, S. 847-53.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.
AU - Eichelberg, Christian
AU - Minner, Sarah
AU - Isbarn, Hendrik
AU - Burandt, Eike
AU - Terracciano, Luigi
AU - Moch, Holger
AU - Kell, Alexandra
AU - Heuer, Roman
AU - Chun, Felix K
AU - Sauter, Guido
AU - Fisch, Margit
AU - Tennstedt, Pierre
PY - 2013
Y1 - 2013
N2 - PURPOSE: Alpha-methyl CoA racemase (AMACR) is used as an immunohistochemical marker for renal cell carcinoma (RCC) subtyping to distinguish papillary (pap) RCC. Expression of AMACR in other renal tumor subtypes is inhomogeneous, and the clinical and prognostic value of AMACR is unknown. The aim of this study was to asses AMACR protein expression in different RCC subtypes and to investigate its prognostic significance.METHODS: Protein expression of AMACR was analyzed in 1,088 renal tumor samples, among them 809 clear cell RCC and 151 papRCC, by immunohistochemistry using tissue microarry (TMA) technique. Results were correlated with clinicopathological data and to follow-up data [overall (OS)/cancer-specific survival (CSS)].RESULTS: Frequency of AMACR expression was significantly higher in papRCC compared to other tumor subtypes (83% vs. 15-35%, p < 0.0001). Presence of AMACR did not correlate with stage or nodal metastases in papRCC. In a dichotomized scoring (negative vs. positive expression), an inverse correlation between higher grade (p = 0.03) and presence of distant metastasis (p = 0.014) was observed in papRCC. AMACR expression correlated with the presence of nodal metastasis in ccRCC (p = 0.02). Both in ccRCC and in papRCC, OS and CSS did not correlate with the AMACR expression status.CONCLUSIONS: The high expression in papRCC confirms AMACR to be a marker for subtype differentiation in RCC, while a missing expression in this subtype seems to be associated with negative pathological features. However, in contrast to other tumor entities, AMACR expression seems to have a limited prognostic impact in renal carcinoma, especially with regard to survival.
AB - PURPOSE: Alpha-methyl CoA racemase (AMACR) is used as an immunohistochemical marker for renal cell carcinoma (RCC) subtyping to distinguish papillary (pap) RCC. Expression of AMACR in other renal tumor subtypes is inhomogeneous, and the clinical and prognostic value of AMACR is unknown. The aim of this study was to asses AMACR protein expression in different RCC subtypes and to investigate its prognostic significance.METHODS: Protein expression of AMACR was analyzed in 1,088 renal tumor samples, among them 809 clear cell RCC and 151 papRCC, by immunohistochemistry using tissue microarry (TMA) technique. Results were correlated with clinicopathological data and to follow-up data [overall (OS)/cancer-specific survival (CSS)].RESULTS: Frequency of AMACR expression was significantly higher in papRCC compared to other tumor subtypes (83% vs. 15-35%, p < 0.0001). Presence of AMACR did not correlate with stage or nodal metastases in papRCC. In a dichotomized scoring (negative vs. positive expression), an inverse correlation between higher grade (p = 0.03) and presence of distant metastasis (p = 0.014) was observed in papRCC. AMACR expression correlated with the presence of nodal metastasis in ccRCC (p = 0.02). Both in ccRCC and in papRCC, OS and CSS did not correlate with the AMACR expression status.CONCLUSIONS: The high expression in papRCC confirms AMACR to be a marker for subtype differentiation in RCC, while a missing expression in this subtype seems to be associated with negative pathological features. However, in contrast to other tumor entities, AMACR expression seems to have a limited prognostic impact in renal carcinoma, especially with regard to survival.
KW - Carcinoma, Renal Cell
KW - Cohort Studies
KW - Follow-Up Studies
KW - Gene Expression Regulation, Neoplastic
KW - Humans
KW - Kaplan-Meier Estimate
KW - Kidney Neoplasms
KW - Neoplasm Staging
KW - Predictive Value of Tests
KW - Prognosis
KW - Racemases and Epimerases
KW - Retrospective Studies
KW - Survival Rate
KW - Tumor Markers, Biological
U2 - 10.1007/s00345-011-0783-z
DO - 10.1007/s00345-011-0783-z
M3 - SCORING: Journal article
C2 - 22009118
VL - 31
SP - 847
EP - 853
JO - WORLD J UROL
JF - WORLD J UROL
SN - 0724-4983
IS - 4
ER -
